Berman Capital Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
$956K Buy
4,142
+482
+13% +$119K 0.15% 76
2021
Q2
$840K Buy
3,660
+496
+16% +$99.6K 0.13% 78
2021
Q1
$590K Buy
3,164
+489
+18% +$95.7K 0.12% 88
2020
Q4
$451K Buy
2,675
+100
+4% +$14.9K 0.11% 94
2020
Q3
$380K Buy
2,575
+969
+60% +$150K 0.11% 86
2020
Q2
$263K Buy
1,606
+163
+11% +$25K 0.07% 115
2020
Q1
$198K Buy
1,443
+477
+49% +$65.5K 0.06% 120
2019
Q4
$126K Buy
966
+2
+0.2% +$232 0.04% 196
2019
Q3
$107K Sell
964
-87
-8% -$9.69K 0.03% 205
2019
Q2
$116K Buy
1,051
+125
+13% +$14.7K 0.04% 191
2019
Q1
$120K Buy
926
+347
+60% +$42.2K 0.04% 170
2018
Q4
$66K Buy
+579
New +$64.7K 0.03% 226

Other funds holding LLY

Berman Capital Advisors's LLY Position: Q3 2021 in Review

Berman Capital Advisors increased its Eli Lilly (LLY) stake by 13% in Q3 2021, buying an estimated $119K and bringing the position to 4,142 shares worth $956K. The position accounts for 0.15% of the portfolio, ranked #76.

Berman Capital Advisors first reported a position in LLY in Q4 2018 and has held it in 12 quarters since. 2,051 funds tracked by Wall St. Rank hold LLY as of Q3 2021.

  • Berman Capital Advisors held 4,142 shares of Eli Lilly worth $956K as of Q3 2021.
  • Berman Capital Advisors bought 482 Eli Lilly shares in Q3 2021, an estimated $119K.
  • Eli Lilly made up 0.15% of Berman Capital Advisors's portfolio in Q3 2021, its #76 holding.
  • Berman Capital Advisors first reported a position in Eli Lilly in Q4 2018 and has held it in 12 quarters since.
  • 2,051 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.